Cambridge Cognition Holdings PLC (AIM:COG) has announced a £1.1mln contract with a major pharmaceutical company to provide electronic clinical outcome assessments (eCOA) and hardware for a rare blood disease study running over two years.
The new contract, with an existing customer, is for a mixture of eCOA licenses, services and hardware to support an upcoming clinical trial, the developer of digital brain health assessment said.
The AIM-listed company will provide the platform and hardware for capturing participants' experiences and their responses to standardised questionnaires and scales.
READ: Cambridge Cognition strengthens virtual clinical trials offering with £1.7mln acquisition
"Cambridge Cognition has a strong history of delivering cognitive assessments in the field, traditionally in clinics and now also at home,” commented Matthew Stork, chief executive officer of Cambridge Cognition in a statement.
“We are pleased to see this new order from an existing client, our reputation for quality, service and scientific rigour is enabling us to win eCOA-only clinical trials," he added.
The company said the provision of eCOA for clinical trials is a sizeable growth market, valued at over US$1bn a year and growing at more than 15%, according to market research.